Key result
A single 20 mg dose of tadalafil did not modify flow-mediated dilation in grade 1 obesity but significantly lowered systolic blood pressure (125.0 vs 130.6 mmHg; p=0.011).
Why the study?
Obesity is associated with increased cardiovascular risk, endothelial dysfunction, and arterial stiffness, but the acute effects of tadalafil on these vascular parameters required evaluation.
Does a single 20 mg dose of tadalafil improve flow-mediated dilation, hemodynamics, and arterial stiffness in patients with grade 1 obesity?
RCT (n=80)
double-blind
randomized
Does a single 20 mg dose of tadalafil improve flow-mediated dilation, hemodynamics, and arterial stiffness in patients with grade 1 obesity?
Absolute Event Rate: 125% vs 130.6%
p-value: p=0.011
A single 20 mg dose of tadalafil improves blood pressure and arterial stiffness but not flow-mediated dilation in patients with grade 1 obesity.
OBJECTIVE: Obesity, a major health issue worldwide, is associated with increased cardiovascular risk, endothelial dysfunction, and arterial stiffness. Tadalafil has been demonstrated to improve vascular parameters. AIM: To evaluate the effect of a single 20 mg dose of tadalafil on flow-mediated dilation and hemodynamic and arterial stiffness markers. METHODS: A randomized, double-blind, placebo-controlled study was conducted on 80 participants (41 assigned to placebo and 39 to tadalafil) with grade 1 obesity, to evaluate the acute effect of a single dose of 20 mg of tadalafil on flow-mediated dilation and hemodynamic and arterial stiffness markers. RESULTS: Tadalafil did not modify flow-mediated dilation. However, it significantly lowered systolic blood pressure (SBP) (130.6±17.1 vs. 125.0±12.7 mmHg, p=0.011), diastolic blood pressure (82.7±18.2 vs. 76.5±11.8 mmHg, p≤0.001), central systolic blood pressure (116.33±19.16 vs. 109.90±15.05 mmHg, p=0.001), the augmentation index (69.1±17.1 vs. 65.7±14.4, p=0.012), and brachial-ankle pulse wave velocity (1229.7±218.4 vs. 1164.0±181.7, p=0.001). CONCLUSION: A single dose of tadalafil did not modify flow-mediated dilation in patients with grade 1 obesity but improved blood pressure and brachial-ankle pulse wave velocity.
No takes yet. Share an insight, caveat, or question.
Larios-Cárdenas et al. (2022) conducted an RCT in grade 1 obesity (n=80). Tadalafil vs. placebo was evaluated on flow-mediated dilation and hemodynamic and arterial stiffness markers (systolic blood pressure reported) (p=0.011). A single 20 mg dose of tadalafil did not modify flow-mediated dilation in grade 1 obesity but significantly lowered systolic blood pressure (125.0 vs 130.6 mmHg; p=0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: